ArticleRespiratory research2025
Trends in interstitial lung disease and the COVID-19 pandemic in the United States from 1999 to 2022.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interstitial Lung Disease in the United States: CDC Mortality Trends (1999-2024).Advances in respiratory medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough the population was aging, interstitial lung disease mortality had remained relatively stable until it rose following the COVID-19 pandemic in the United States. Despite the consistent overall mortality trend prior to the pandemic, significant demographic and geographic disparities persist across the country.
methodsDisparities in ILD-related mortality were analyzed temporally using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiological Research (CDC WONDER) database. Using ICD Codes J84.1, J84.8, and J84.9 ILD-related crude mortality (CMR) and age-adjusted mortality rates (AAMR) were calculated, and the Join-point Regression Program was used to determine mortality trends between 1999 and 2022. ILD-related mortality was identified using the International Classification of Diseases, 10th Revision, and clinical modification codes J84.1 (Other interstitial pulmonary diseases with fibrosis), J84.8 (Other specified interstitial pulmonary diseases), and J84.9 (Interstitial pulmonary disease, unspecified) were used in patients ≥ 45 years.
resultsBased on the results of this study, there have been 609,157 deaths due to ILD during this study period, with the highest mortality rates seen in the Non-Hispanic (NH) American Indian or Alaskan Native population, and the lowest mortality rates seen in the NH African American population. Hispanic or Latinos and NH Whites experienced similar mortality. Males had higher mortality rates than females in all racial groups. Regarding region, the Northeast had significantly lower mortality rates than all other census areas throughout the entire study period. The results of this study demonstrate large increases in AAMR at the onset of COVID-19 beginning in 2020, peaking in 2021, and decreasing in 2022.
conclusionsThe COVID-19 pandemic posed unique challenges to our society, especially for patients with interstitial lung disease. While further research is needed to better understand these trends, it is concerning that ILD-related mortality increased throughout the study period. Medical professionals should be cognizant of these trends when treating patients diagnosed with ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.